Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 9, Issue 2, Pages 187-198Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.9.2.187
Keywords
adjuvant; anastrozole; aromatase; estrogen; exemestane; fulvestrant; hormone therapy; letrozole; raloxifine; tamoxifen
Categories
Ask authors/readers for more resources
The treatment of women with estrogen receptor-positive breast cancer has advanced significantly in the past decade. Tamoxifen was the gold standard hormonal therapy for breast cancer until the introduction of aromatase inhibitors and fulvestrant. Many of these new treatments are useful only for patients who are postmenopausal. There are data to support the use of these new agents both in the metastatic and adjuvant settings. Here, we briefly review the recent clinical trials supporting the use of these agents in both the adjuvant and metastatic settings. We will discuss possible mechanisms of resistance to endocrine agents that could be exploited therapeutically to improve the outcome for patients with hormone receptor-positive breast cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available